Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Entia Biosciences's Revenue for the
three
months ended in Dec. 2016 was $0.05 Mil. Entia Biosciences's average Accounts Receivable for the
three
months ended in Dec. 2016 was $0.01 Mil.
Hence, Entia Biosciences's Receivables Turnover for the
three
months ended in Dec. 2016 was 6.57.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Entia Biosciences Receivables Turnover Related Terms
Entia Biosciences Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Entia Biosciences's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ERGO vs OBMP, NSPX, ATRX: Receivables Turnover Comparison
For the Biotechnology subindustry, Entia Biosciences's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entia Biosciences Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entia Biosciences's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Entia Biosciences's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entia Biosciences (ERGO) has a Receivables Turnover of 6.57 as of Dec. 2016. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Entia Biosciences and its competitors.
Is Entia Biosciences' Receivables Turnover too high?
Entia Biosciences' current Receivables Turnover is 6.57. The Biotechnology industry median Receivables Turnover is 5.29. Entia Biosciences' value of 6.57 is 24.2% above this industry median.
How does Entia Biosciences' Receivables Turnover compare to OBMP and NSPX?
Entia Biosciences' Receivables Turnover of 6.57 can be compared against companies in the Biotechnology industry. The industry median Receivables Turnover is 5.29. Entia Biosciences' value of 6.57 is 24.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Entia Biosciences's current Receivables Turnover of 6.57 is 24.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Entia Biosciences and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Entia Biosciences's current Receivables Turnover is 6.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entia Biosciences stock overvalued right now?
Entia Biosciences (ERGO) has a current Receivables Turnover of 6.57. The current Receivables Turnover is 6.57 and 24.2% above the Biotechnology industry median of 5.29. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Entia Biosciences (ERGO), the current Receivables Turnover is 6.57 as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Entia Biosciences Inc operates as a biotechnology company, is engaged in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products, principally in the United States of America. It market nutraceutical products under the name GROH and SANO directly to the consumers online. It currently offers natural organic nutraceutical mushroom dietary supplement products, ImmuSANO, GlucoSANO, and GROH, which has been designed to nutritionally support hair follicles and nail beds. It derives its revenue from the sale of its GROH line and mushroom-based nutraceutical dietary supplement products and functional ingredients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ERGO has been successfully added to your 
